Tract Bio ("Tract"), a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced presentations at the American Association for Cancer ...
Successful autologous hematopoietic stem cell transplant (ASCT) requires a sufficient number of stem cells from peripheral blood to be collected. In many cases, stem cell collection may be difficult ...
TEL AVIV, Israel, Feb. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that ...
Students in the Summer Science Program present collaborative research projects developed during the program’s intensive residential research experience. Teams work together on projects in fields such ...
GENESIS (NCT 03246529) is a 2-part, Phase-3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), ...
Nachrichten»BioLineRx Ltd.: BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results